Diesel Exhaust Particulates Exacerbate Asthma-Like Inflammation by Increasing CXC Chemokines

Jiyoun Kim,* Sudha Natarajan,† Louis J. Vaickus,† Jacqueline C. Bouchard,† Dominic Beal,† William W. Cruikshank,‡ and Daniel G. Remick*

From the Department of Pathology and Laboratory Medicine* and The Pulmonary Center,† Boston University School of Medicine, Boston, Massachusetts

Particulate matter heavily pollutes the urban atmosphere, and several studies show a link between increased ambient particulate air pollution and exacerbation of pre-existing pulmonary diseases, including asthma. We investigated how diesel exhaust particulates (DEPs) aggravate asthma-like pulmonary inflammation in a mouse model of asthma induced by a house dust extract (HDE) containing cockroach allergens and endotoxin. BALB/c mice were exposed to three pulmonary challenges via hypopharyngeal administration of an HDE collected from the home of an asthmatic child. One hour before each pulmonary challenge, mice were exposed to DEP or PBS. Pulmonary inflammation was assessed by histological features, oxidative stress, respiratory physiological features, inflammatory cell recruitment, and local CXC chemokine production. To prove the role of CXC chemokines in the augmented inflammation, CXC chemokine-specific antibodies were delivered to the lungs before DEP exposure. DEP exacerbated HDE-induced airway inflammation, with increased airway mucus production, oxidative stress, inflammatory cell infiltration, bronchoalveolar lavage concentrations of CXC chemokines, and airway hyperreactivity. Neutralization of airway keratinocyte-derived chemokine and macrophage inflammatory protein-2 significantly improves the respiratory function in addition to decreasing the infiltration of neutrophils and eosinophils. Blocking the chemokines also decreased airway mucus production. These results demonstrate that DEP exacerbates airway inflammation induced by allergen through increased pulmonary expression of the CXC chemokines (keratinocyte-derived chemokine and macrophage inflammatory protein-2).

Asthma is a unique form of chronic respiratory disease characterized by reversible airway obstruction, airway inflammation, and airway hyperresponsiveness (AHR). It represents one of the most common chronic inflammatory diseases, affecting an estimated 300 million people worldwide, with an expected significant increase to 400 million people by 2025. The sharply increasing prevalence and incidence of asthma causes global concern, both in developing and developed countries. In the United States, the prevalence of asthma among children increased from 3.6% in 1980 to 9.6% in 2009.

To shed light on the cause of recent increases of allergic conditions, such as asthma and allergic rhinitis, several factors have been proposed, including genetic and environmental changes. Although the relative contribution of genetics and the environment in the development of asthma remains to be elucidated, numerous studies have documented the effects of environmental exposures on the risk of pulmonary diseases. As several epidemiological and clinical studies emerged, it has become clear that increased ambient air pollutants, including particulate matter, are correlated with dramatic increases in the risk of respiratory and cardiovascular diseases. Recently, epidemiological research demonstrated an association between the degree of traffic exposure and the lung function of asthmatic patients.

Among common air pollutants, suspended particulate pollutants and ambient particulate matter (PM) are the most serious pollutants that have been consistently correlated with adverse health effects. Diesel exhaust particulates (DEPs) from the diesel-powered motor vehicles constitute the largest single source of PM in the atmosphere of cities. Consequently, DEP is widely used for studying the effects of PM. DEP is a complex mixture of solid and liquid PM, including elemental car-

Supported by a grant from the NIH (R01 ES013528).

Accepted for publication August 10, 2011.

CME Disclosure: None of the authors disclosed any relevant financial relationships.

Supplemental material for this article can be found at http://ajp.amjpathol.org or at doi: 10.1016/j.amjpathol.2011.08.008.

Address reprint requests to Jiyoun Kim, Ph.D., Department of Pathology and Laboratory Medicine, Boston University School of Medicine, 670 Albany St, Room 404, Boston, MA 02118. E-mail: jykim@bu.edu.
bon, polycyclic aromatic hydrocarbons, acid aerosols, volatile organic compounds, and gases (ie, carbon dioxide and nitrogen dioxide). The effects of air pollutants on the development and exacerbation of asthma have been demonstrated in animal and human studies. Although the effects are clearly demonstrable, the mechanisms responsible for air pollution–induced asthma exacerbations have yet to be elucidated.

Substantial evidence, including the oxidant properties of PM, implicates reactive oxygen species (ROS) in DEP-induced pulmonary inflammation. Highly elevated oxidative stress will induce pro-inflammatory cytokines and chemokines in addition to its direct effects on airway smooth muscle and mucin secretion. Chemokines may be particularly important in the regulation of inflammatory responses induced by DEP. Enhances CXCL8 (IL-8) and chemokine ligand 2 (monokine induced pulmonary inflammation). Highly elevated levels of PM, implicates reactive oxygen species (ROS) in DEP-exacerbations have yet to be elucidated.

To investigate the biological mechanisms responsible for the exacerbation of pulmonary inflammation and AHR in a mouse model of asthma, we determined whether asthma-like inflammatory responses in mice are exacerbated by the combination of the air pollutant DEP and allergen challenge. Because CXC chemokines help drive the asthmatic response in the absence of air pollution, we specifically examined if these mediators were the mechanism of DEP aggravation of asthma. Our data demonstrate, for the first time to our knowledge, that KC and MIP-2, two CXC chemokines, orchestrate DEP-induced exacerbation of airway inflammation and AHR in vivo.

Materials and Methods

Mice
Female BALB/c mice (aged 8 weeks) were obtained from Jackson Laboratory (Bar Harbor, ME) and maintained under standard laboratory conditions. The mice were housed in a temperature-controlled room (22°C) with a 12-hour dark-light cycle, with food and water allowed ad libitum. All experiments were performed in accordance with the NIH guidelines and approved by the Boston University or University of Michigan Committee on the Use and Care of Animals.

Sensitization Procedures
The household dust used for all sensitizations and airway challenges was collected from a house in Detroit, MI, and then extracted as previously reported. Each mouse received 50 μL of house dust extract (HDE) that contains 1.9 U of Bla g1, 31 ng of Bla g2, and 0.91 ng of endotoxin.

We used our previously described model of asthma to induce the response with the significant modification of eliminating the use of an adjuvant. The pulmonary-only exposure protocol has strongly induced asthma-like pulmonary inflammation. Briefly, mice were sensitized with three hypopharyngeal instillations of HDE on days 0, 14, and 21. AHR was measured 2 hours after the last challenge on day 21, and mice were then sacrificed to collect samples.

DEP Challenge
DEPs were obtained from the National Institute of Standards and Technology (Standard Reference Material 2975, Gaithersburg, MD) and prepared in PBS with 0.05% Tween-80, a nontoxic and nonionic surfactant, following established procedures. The suspension was sonicated for 2 minutes (Misonix, Newtown, CT) immediately before use. One hour before each HDE challenge, mice received a total of 0.05 mg of DEP suspension by hypopharyngeal instillation on days 0, 14, and 21. Control mice received 50 μL of PBS with 0.05% Tween-80. The DEP suspension contains 107 ng/mL of endotoxin (5.4 ng per mouse), and the pH is 6.8.

Antibody Treatment
Groups of BALB/c mice were sensitized and challenged as previously described. One hour before the third challenge of DEP on day 21, mice were given a combination of 10 μg of rat anti-mouse KC monoclonal antibody and 4 μg of rat anti-mouse MIP-2 monoclonal antibody (anti-KC/MIP-2 Ab; R&D Systems, Inc., Minneapolis, MN) by hypopharyngeal challenge. For controls, mice received 14 μg of rat IgG (Jackson Immuno Research Laboratories) via the same route.

Measurement of Respiratory Function
AHR was measured 2 hours after the final allergen challenge by two separate methods. Whole-body plethysmography (WBP; Buxco, Troy, NY) was used to measure AHR in response to increasing doses of aerosolized acetyl β-methylcholine (Methacholine; Sigma, St Louis, MO) in unrestrained and conscious mice, as previously reported.

Changes of airway resistance were measured by a forced oscillation technique on a Flexivent instrument (Scireq Scientific Respiratory Equipment, Montreal, QC, Canada). Mice were anesthetized with an i.p. injection of 1:5 diluted pentobarbital (Nembutal, 0.016 mL/g body weight; Ovation Pharmaceutical, Deerfield, IL). The paralytic was pancuronium (Sigma-Aldrich, St Louis) at 0.5 μg/g body weight. When adequate surgical sedation was reached, as determined by a firm squeeze of the foot pad, a tracheotomy was performed, followed by insertion of an 18-gauge polyethylene cannula into the distal trachea. The mouse was then placed on the Flexivent mechanical ventilator (Scireq Scientific Respiratory Equipment) and ventilated at 190 breaths/minute with positive-end expiratory pressure set at 3 cm H2O. The measurement of airway resistance in response to increasing doses of aerosolized methacholine was obtained through periodic computer-generated “snap-
shot 150° forced-maneuver interruptions in ventilation. Data are then presented as resistance change from baseline (in cm H$_2$O/mL per second).

Sample Collection and Analyses

Blood and BALF

Blood and bronchoalveolar lavage fluid (BALF) were collected and processed as previously reported.$^{25}$

Preparation of Lung Homogenates and MPO Assay

After the BALF was collected, the right lung was removed and immediately processed, as previously reported.$^{26}$ The myeloperoxidase (MPO) activity was assayed as described by Schneider and Issekutz,$^{27}$ with minor modifications. The supernatant from sonicated and centrifuged lung homogenates was diluted with 10 mmol/L citrate buffer, pH 5.0, on a 96-well plate. An equal volume (75 µL) of substrate solution containing 3,3',5,5'-tetramethylbenzidine, 120 mmol/L resorcinol (an eosinophil peroxidase inhibitor), and 0.007% H$_2$O$_2$ in deionized H$_2$O was added to the sample and incubated in the dark for 2 minutes. Ice-cold 4N H$_2$SO$_4$ (150 µL) was added to stop the reaction, and the absorbance at 450 nm was measured. MPO data are expressed as ΔOD, reflecting the difference in absorbance between the sample and the blank wells.

Histopathological Analysis

Immediately after collecting the BALF, the left lung from each mouse was removed, fixed in 70% ethanol, and processed for routine histological analysis in paraffin. Tissue sections were stained with H&E or PAS and then examined under light microscopy. Digital images were taken of each of the lungs from each animal. The entire histological section on the glass slide was selected, and areas were quantified using NIH ImageJ software ($^{22}$http://rsbweb.nih.gov/ij, last accessed December 9, 2010), as previously described.$^{22}$

Measuring 8-Isoprostane Concentrations in BALF

The concentration of 8-isoprostane in BALF was measured by a commercially available specific enzyme immunoassay kit (Cayman Chemical Co, Ann Arbor, MI).

Cytokine and Chemokine Analysis

All chemokine, cytokine, and IgE measurements were performed simultaneously to reduce errors due to inter-assay variation. The concentrations of all chemokines and cytokines were measured by enzyme-linked immunoasorbent assay using matched antibody pairs (R&D Systems, Inc.), as previously described.$^{20}$

Microarray Data Analysis

The microarray analysis was performed as previously reported.$^{22}$ Briefly, using freeware, TM4-MeV 4.6.2 ($^{22}$http://www.tm4.org/mev.html, last accessed December 9, 2010), the heat map and the hierarchal clustering map were generated after Z-score normalization was performed.

Statistical Analyses

Mean ± SEM was used for summary statistics in all figures. Differences between all treatment groups were compared by unpaired Student’s t-test or one-way analysis of variance with Tukey’s posttest using GraphPad Prism version 5.0 software (GraphPad Software, San Diego, CA). Statistical significance was achieved when $P \leq 0.05$ at the 95% CI.

Results

DEP Exposure Exacerbates Cockroach Allergen–Induced Asthma-Like Pulmonary Inflammation

Three pulmonary exposures to an HDE containing high levels of cockroach allergens induce substantial asthma-like pulmonary inflammation. This inflammation is characterized by infiltrates of lymphocytes, eosinophils, and neutrophils in the peribronchial and perivascular space (Figure 1A). Mice exposed to DEP have the same inflammatory pattern; however, macrophages containing phagocytosed material are clearly evident as intracellular anthracotic pigment (Figure 1B). Airway mucus production in the model was determined by PAS staining. DEP/asthma mice (Figure 1D) showed a marked increase of mucus staining compared with PBS/asthma mice (Figure 1C). The increased mucus production was confirmed by computer-aided morphometric quantification of the PAS staining (Figure 1E).

Increased Pulmonary Oxidative Stress

Cellular oxidative stress is considered a primary factor in the biological effects of air pollutants.$^{11}$ An imbalance in oxidative stress and antioxidant defenses induces a wide spectrum of pro-inflammatory mediators.$^{14}$ Since first discovered in 1990,$^{28}$ 8-isoprostane (8-iso prostaglandin F2α) has been considered a reliable marker to assess the in vivo status of oxidative stress.$^{29}$ To investigate potential exacerbation of asthma-like pulmonary inflammation by DEP, isoprostane levels in BALF were measured 4 hours after the last allergen challenge. Isoprostane concentrations in BALF were significantly greater in DEP/asthma compared with asthma alone (Figure 2). As a control, mice were exposed only to DEP without allergens. This group of mice did not have elevated isoprostane levels, indicating that the combination of stimulation with the allergen in the presence of the pollutants induces the highest level of oxidative stress.

DEP Enhances AHR

DEP-induced ROS have exacerbated asthma by sensitizing airway smooth muscle to acetylcholine-induced contraction.$^{17}$ When delivered concomitantly or after allergen challenge, DEP exacerbated AHR in addition to pulmonary inflammation.$^{30,31}$ AHR was measured by
WBPs and confirmed with a direct invasive method, given the controversy of WBPs. Bronchopulmonary hyperresponsiveness to methacholine (50 mg/mL) challenge was measured 2 hours after the last challenge and was significantly increased in DEP/asthma mice compared with PBS/asthma mice (Figure 3A). The DEP-only group showed no significant changes in enhanced pause (data not shown). Forced oscillation experiments compared the airway resistance of the DEP/asthma with the PBS/asthma group, which verified the WBP studies by demonstrating a significant increase in airway resistance in the DEP/asthma mice (Figure 3B).

Exacerbation of Pulmonary Neutrophil Infiltration

The early response to asthma includes recruitment of neutrophils to the pulmonary airspace. We examined whether DEP would increase the inflammatory response in the early phase by assessing parameters 4 hours after the allergen challenge. DEP/asthma mice had significantly more neutrophils within the BALF compared with PBS/asthma mice (Figure 4A). Pulmonary MPO, which measures neutrophils and monocytes sequestered in the interstitium, was also significantly increased by exposure to DEP plus the allergen challenge. The numbers of other inflammatory cells in the BALF, including eosinophils, lymphocytes, and macrophages, were not increased by the DEP and allergen challenge (data not shown).

To investigate the potential role of CXC chemokines in the enhanced neutrophil recruitment induced by DEP/asthma, we measured the concentrations of KC and MIP-2 in the BALF and lung tissue during the early response. The BALF levels of both chemokines were significantly increased (Figure 4B) in the DEP/asthma mice. In addition, MIP-2 levels were elevated in the lung homogenate in the DEP/asthma group (Figure 4C). We also analyzed the BALF levels of CC chemokines, including regulated on activation normal T-cell expressed and secreted and MIP-1α, as previous reports demonstrated and found no significant differences between the two groups (data not shown). DEP exposure in asthma mice also had systemic effects, because the plasma levels of MIP-2 and total IgE were increased compared with PBS/asthma or DEP only (data not shown).

CXC Chemokines Are Responsible for Enhanced Pulmonary Neutrophil Recruitment in Airway Inflammation and AHR by DEP

Particulate matter–induced oxidative stress has augmented CXC chemokines (ie, IL-8, KC, and MIP-2) in cystic fibrosis airway cells and airway epithelial cells. As previously shown, in this model, KC and MIP-2 were significantly increased locally (BALF and lung homogenates) in the DEP/asthma group. We hypothesized that DEP/asthma may promote the development
and exacerbation of allergic pulmonary inflammation via up-regulation of CXC chemokines.

To rigorously test this hypothesis, mice were treated with a combination of neutralizing antibodies to KC and MIP-2 at 1 hour before DEP challenge on day 21 by the oropharyngeal route. At 1 hour after the DEP exposure, mice were challenged with HDE-containing cockroach allergens; at 2 hours after the HDE challenge, respiratory parameters were measured via WBP. After WBP, mice were sacrificed, which was 4 hours after the allergen challenge. For this study, mice challenged with PBS/asthma or DEP only were not included because KC and MIP-2 were substantially elevated only in the DEP/asthma group.

All respiratory parameters, the number of inflammatory cells in airways, and the inflammatory mediator data set from the IgG-treated and anti-CXC chemokine–treated mice were converted to a heat map to perform a comprehensive unbiased analysis, as previously reported.22 The raw values that were subjected to Z-score transformation include all respiratory parameters (ie, respiratory rate, tidal volume, minute ventilation, time inspiration, time expiration, peak inspiratory flow, peak expiratory flow, and enhanced pause); differential counting of BALF (ie, number of total cells, eosinophils, lymphocytes, macrophages, and neutrophils); neutrophil MPO; eosinophil-specific peroxidase; inflammatory mediators in BALF, plasma, and lung homogenates; and quantified PAS staining. Once Z-score normalization was completed, a heat map was generated from the averaged Z-score by using the TM4-MeV program and further simplified by unbiased hierarchal clustering based on sample groups and parameters.

Figure 3. DEP significantly exacerbates asthma AHR. Enhanced pause (Penh, A) and resistance (R, B) values in response to methacholine (50 and 25 mg/mL, respectively) were obtained 2 hours after the last challenge via the WBP (A) or forced oscillation (B) techniques. Data are the mean ± SEM (n = 8 per group for A, from two separate experiments, and n = 4 per group for B). *P ≤ 0.05 when compared with the PBS/asthma group.

The final analysis of the clustered heat map demonstrated the pattern that anti-KC/MIP-2 antibody–treated mice shared more common features with healthy naïve mice (see Supplemental Figure S1 at http://ajp.amjpathol.org), and airway obstruction and pulmonary inflammatory cell infiltrations induced by DEP were significantly improved by anti-KC/MIP-2 Ab treatment. To further demonstrate the improvement of respiratory function by anti-CXC chemokine Ab treatment, we analyzed and compared the minute ventilation and time expiration in control IgG-treated, anti-CXC antibody–treated, and naïve mice. As shown in Figure 5, A and B, anti-KC/MIP-2 Ab treatment significantly improved minute ventilation and time expiration. Among the common features of respiratory parameters, minute ventilation and time expiration are correlated with improved airway obstruction.22

Analysis of the clustered heat map also suggested that pulmonary infiltration of inflammatory cells was significantly improved by anti-CXC antibody treatment. CXC chemokines are major neutrophil chemotactants, and it is anticipated that antibody inhibition of their biological activity would decrease pulmonary inflammatory cell recruitment, particularly neutrophils. This was examined by quantifying the cells recovered from the BALF obtained 4 hours after the last allergen challenge. Neutralization of CXC chemokines resulted in fewer cells in the BALF (Figure 5C). CXC chemokines will increase the chemotaxis of eosinophils,37,38 and our studies show that antibody blockade of the CXC chemokines reduced the number of eosinophils in the BALF (Figure 5D). Given the prominent role of KC and MIP-2 as neutrophil chemoattractants, we anticipated that the number of neutrophils

Figure 4. Increased pulmonary neutrophils and CXC chemokines in the DEP/asthma group 4 hours after allergen challenge. Asthma challenge after DEP exposure significantly increases pulmonary neutrophil recruitment and MPO activity in the lungs (A). The CXC chemokines KC and MIP-2 were also significantly increased in the BALF (B) and within the lung homogenate (C). The data are expressed as the mean ± SEM for six to eight mice per group from two separate experiments. *P ≤ 0.05, **P ≤ 0.01 when compared with the PBS/asthma group.
recruited to the lung in response to the DEP and HDE challenge would be significantly decreased. As expected, the number of neutrophils recovered from the BALF was significantly reduced in the mice treated with anti-KC/MIP-2 Ab (Figure 5E). Along with the reduction of neutrophils in the airway, there was a marked reduction in lung MPO activity, which reflects neutrophil sequestration within the lung (Figure 5F). There was no significant reduction in the numbers of lymphocytes or macrophages, the expected result because these cells do not respond to CXC chemokines (data not shown). These data demonstrate that neutralization of the CXC chemokines in the airway reduced the number of inflammatory cells in the lung tissue and airways.

In our previous report, we demonstrated that excess production of mucus in airways is correlated with the airway obstruction, and a decrease in mucus production significantly improved air exchange in dexamethasone-treated mice. With improved respiratory function and fewer pulmonary neutrophils and eosinophils after neutralization of KC and MIP-2, we then examined how the antibody treatment affects airway mucin expression via PAS staining. The anti-CXC antibody–treated mice (Figure 6B) had significantly less production of airway mucin compared with the control antibody–treated mice (Figure 6A), with levels similar to the amounts quantified in Figure 1E. The reduction in the levels of mucin expression with antibody inhibition of CXC chemokines was further dem-

![Figure 5](image)

**Figure 5.** Anti-KC and MIP-2 antibody treatment significantly improved lung functions [minute ventilation (MV; A) and time of expiration (Te; B)] and pulmonary inflammatory cell recruitment (C–F). Mice received a combination of anti-mouse KC and MIP-2 monoclonal antibodies or control rat IgG before DEP exposure and allergen challenge. Lung function (MV and Te) changes in response to nebulized methacholine (50 mg/mL) were measured 2 hours after the final allergen challenge via WBP. Cells in BALF recovered after 4 hours were quantified. Antibody treatment significantly improved MV (A), Te (B), total BALF cells (C), eosinophils (D), and neutrophils (E). Lung MPO was also reduced significantly (F). The data are expressed as the mean ± SEM for eight mice per group from two separate experiments. *P ≤ 0.05, **P ≤ 0.01 when compared with the IgG-treated group.

![Figure 6](image)

**Figure 6.** CXC chemokine inhibition reduces airway mucus expression. PAS-stained lungs from control IgG-treated mice show abundant mucus production (A). Anti-KC and MIP-2 antibody-treated mice show significantly reduced mucus in the airway (B). Computer-assisted quantification of PAS staining showed a significant reduction of PAS staining with anti-KC/MIP-2 treatment (C). Each value is the mean ± SEM for eight mice per group from two separate experiments. *P ≤ 0.01 when compared with the control IgG group.
onstrated by computer-assisted morphometric quantification of the PAS staining (Figure 6C).

Discussion

In this study, we investigated the role of CXC chemokines KC and MIP-2 in a mouse model of asthma to define the mechanisms and mediators responsible for the exacerbation of pulmonary inflammation induced by co-exposure of the air pollutant, DEP, and HDE. The current study defined that DEP augmented the pulmonary expression of CXC chemokines, followed by an increase in the number of neutrophils in the airways. Neutralization of KC and MIP-2 chemokines significantly attenuated the pulmonary inflammation, including reduced inflammatory cells, mucin production, and AHR.

A significant association between exposure to air pollutants, including PM, and pre-existing pulmonary diseases, including asthma, has been demonstrated by many epidemiological and clinical studies. While pinpointing the exact mechanisms underlying the pathophysiological characteristics, the evidence for the role of DEP as an adjuvant in promoting sensitization and allergic diseases has been demonstrated in human and animal studies. When DEP is administered concurrently with allergen, the expression of type 2 helper T-cell cytokines is increased, with decreased type 1 helper T-cell cytokines. Furthermore, when mice were exposed to ultrafine particles before allergen challenge, significant increases in inflammatory cells, including neutrophils and eosinophils, airway mucus production, and AHR, were induced.

Although DEP exposure was significantly delayed compared with our study, these results are consistent with the current study.

Although the mechanisms that promote sensitization and allergic diseases by air pollutants are yet to be fully elucidated, a growing body of studies suggests potential epigenetic modifications, including DNA methylation and histone modification induced by exposure to air pollution, play some role in the development of allergy and asthma. A recent study by Liu et al demonstrated that augmented IgE expression in combined exposure to DEP and allergen is potentially induced via DNA hypermethylation of interferon-γ promoter and DNA hypomethylation of IL-4 promoter. Viera et al suggest that expanding the investigation in the epigenetic changes could provide potential insight into the mechanism of promoting the development of allergic inflammation, including asthma, by DEP exposure.

The pulmonary expressions of the CXC chemokines KC and MIP-2 have contributed to neutrophil-mediated acute lung injury. Selective recruitment of neutrophils into the airways during early allergic inflammation suggests that neutrophil-specific chemoattractants are produced and released throughout pulmonary inflammation. Airway accumulation of neutrophils and production of inflammatory mediators, including cytokines and chemokines, are characteristics of an inhaled ozone-induced early inflammatory response. A strong correlation has been established between neutrophil inflammation of the airways and asthma severity, as well as the presence of activated neutrophils. Our studies are in agreement with previous reports, in which neutralization of KC and MIP-2 in the mouse model of asthma, induced by allergen challenge, ovalbumin, or HDE, showed a significant reduction of the number of airway neutrophils.

Considering the fact that DEPs used in this experiment include a low level of lipopolysaccharide (LPS; 5.4 ng per mouse), an increased number of neutrophils infiltrated in the lung might result from the presence of the LPS in the DEPs. However, the number of neutrophils in the lung and the expression of CXC chemokines in the DEP-only mice (that received three DEP challenges) remained close to the baseline, suggesting that the low level of LPS in the DEPs is not the contributing factor to the increased pulmonary recruitment of neutrophils. Although the role of endotoxin in the onset of asthma is complicated because of the difference and complexity in the model, including allergen used, timing of endotoxin exposure, and dose, animal and human studies have shown that endotoxin co-exposure is associated with the exacerbation of pre-existing pulmonary disease, including asthma. Recent human studies demonstrated that endotoxin co-exposure with cockroach allergen or air pollutant synergistically affects pulmonary inflammation and wheezing in children. In our recent study, using BALB/c mice, the administration of endotoxin before allergen challenge significantly reduced AHR, mucus production, and pulmonary eosinophilia. A transitory state of LPS hyporesponsiveness has recently been identified and postulated as a protective mechanism from excessive inflammatory responses via reduced expression of tumor necrosis factor-α and CC chemokine, including eotaxin, while maintaining pulmonary neutrophil recruitment to fight against bacterial challenge.

In addition to the anticipated reduction of the number of neutrophils infiltrated into airway and lungs, the number of eosinophils in BALF was also decreased by neutralization of the CXC chemokines. The decreased pulmonary influx of eosinophils may be the direct result of reduced chemokine levels or an indirect result. In a study using human lung epithelial cells, neutrophils stimulated eosinophils to move toward the complement fragment 5a. In another ex vivo system using isolated neutrophils and eosinophils, IL-8 (CXCL8) stimulated neutrophils to significantly enhance the trans-basement membrane migration of eosinophils. The same authors also reported that the percentage of eosinophils in the sputum of patients with severe persistent asthma strongly correlated with the number of neutrophils and concluded that increased airway accumulation of neutrophils may be a major contributing factor in the development of pulmonary eosinophilia. Our data are in agreement with these results, although they do not fully address the controversy about whether eosinophils are chemotactic to IL-8. Mice lack the exact homolog of human IL-8, and KC and MIP-2 are considered to be the mouse homologs of IL-8.

The recruitment of inflammatory cells, such as neutrophils, and the decline of lung function by oxidative injury from exposure to air pollutants have been shown in clin-
ical studies. Increased ROS production by macrophages, eosinophils, and neutrophils in patients with asthma induces elevated hydrogen peroxide in their breath and superoxide dismutase in their lung cells. Furthermore, eosinophil peroxidase and MPO activities in the BALF of patients with asthma were significantly increased. Although the mechanisms of oxidant toxicity in the pre-existing pulmonary diseases remain to be elucidated, reactions between ROS and surrounding biological compounds, such as proteins, lipids, and DNA, induce various pathological consequences. Based on this finding, enhancing the antioxidant defense systems of the airway would be a therapeutic strategy, especially for populations at risk with increased DEP exposure.

It is also possible that the oxidant enhancement of asthma-like pulmonary inflammation was not the result of a direct toxic effect but rather the result of augmentation of chemokine production. Previous work has demonstrated that ROS will increase the production of CXC chemokines, including IL-8 and the murine CXC chemokines. The proposed sequence of events would involve HDE and DEP augmenting ROS production, which, in turn, would increase CXC chemokine levels and drive the inflammatory process. Blocking the elevated CXC chemokines resulted in significant improvements of several parameters of pulmonary inflammation, including reduced neutrophil and eosinophil numbers, improved respiratory function, and decreased airway mucin production.

**References**

16. Ovrevik J, Lag M, Holme JA, Schwarze PE, Refnes M; Cytokine and chemokine expression patterns in lung epithelial cells exposed to components characteristic of particulate air pollution. Toxicology 2009, 259:46–53

